We want treatments to redefine industry standards. That is why we focus on four therapeutic areas: pain, oncology, respiratory and inflammation.
In these fields, we possess outstanding scientific expertise, which we apply according to the highest ethical standards with the objective of helping to develop innovative medicines that are tailored to the unmet needs of patients and doctors.
At Mundipharma we are thinking differently about pain.
We know it is a necessary part of life, but when pain becomes prolonged and poorly managed we recognise that there is a role for us to play.
The Mundipharma network of independent associated companies has a proven track record of bringing pain innovations to market, successfully launching Palladon®, MST ®, Targin®, BuTrans® and OxyContin®.
But we believe that for people living in pain, and for those treating and caring for them, the job is far from done. Collaborating with our partners, and the people who make treatment decisions, we are working to identify remaining unmet needs.
By building on our heritage we can aspire to bring something different for people in pain.
Mundipharma is already a proven player in the fields of pain management and respiratory medicine - a position we achieved through understanding and responding to patient needs. We are now bringing this expertise to deliver new products to treat cancers. We are dedicated to building a strong presence in this most challenging of therapeutic areas and our aim is to help cancer patients live longer and fuller lives. We have a number of therapies in early and late stage development and we are also actively seeking new opportunities to grow our oncology portfolio.
We are committed to building a presence in respiratory disease, particularly in asthma and COPD. Our associate network has developed a combination therapy for asthma: flutiform▼® (fluticasone/formoterol), which combines fluticasone propionate with formoterol fumarate in a single aerosol inhaler. flutiform▼® is now available in Australia, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Hong-Kong, Iceland, Ireland, Israel, Italy, Luxemburg, the Netherlands, Norway, Slovakia, South Korea, Sweden, Switzerland and the United Kingdom with further launches expected across a number of European countries later in 2014.
Lodotra® (modified-release prednisone) is an innovative programmed-release formulation for the treatment of rheumatoid arthritis in adults, particularly those who suffer from accompanied morning stiffness. Lodotra® is currently available in the following European countries: Austria, Belgium, Denmark, Finland, Germany, Israel, Italy, Luxembourg, the Netherlands, Norway, Poland, Sweden, Switzerland and the United Kingdom.